CHARIOT: ATR inhibitor and radiotherapy in oesophageal cancer
CHARIOT will test the combination of a novel ATR inhibitor with radiotherapy in oesophageal cancer. It aims to find a safe, effective dose of the drug.
CHARIOT is a phase I, single arm, open-label, multicentre, 2-stage, schedule-finding trial using Time-to-Event Continual Reassessment Method (TiTE-CRM). TiTE-CRM is an uncommon method and has not been used by CSM before. It will allow us to recruit fewer patients and to have more patients receive a dose close to the effective dose.
This trial is run by OCTO.
DEBIOC: A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma
DEBIOC is a phase I trial testing whether combining two kinds of therapy before surgery will improve the outcome for patients with oesophago-gastric adenocarcinoma.
The trial is run by OCTO.
Other Clinical Research
TRANSCOG: Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
The drug gefitinib stops tumour cell growth. The phase III clinical trial COG tested whether gefitinib could be used to treat oesophageal cancer, if chemotherapy had failed. The trial found that gefitinib did not improve overall survival across all of the participants. However, it did have palliative benefits in a subgroup of these difficult-to-treat patients with short life expectancy.
This secondary analysis of the COG trial data is looking for predictive biomarkers to identify which patients would be helped by gefitinib.